The content of this website is intended for healthcare professionals only

NICE approves extra ‘triple therapy’ drug for diabetes

Regulator recommends dapagliflozin in triple therapy

Adrian O'Dowd

Thursday, 24 November 2016

NICE has published final guidance that recommends dapagliflozin be used for treating type 2 diabetes as part of what it calls “triple therapy”.

Dapagliflozin can now be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.

In cases where a person’s blood glucose levels are not being controlled sufficiently by metformin (or an alternative drug) and an added second drug, patients can be offered a third drug as part of triple therapy.

NICE’s final guidance means that dapagliflozin joins two other similar drugs, empagliflozin and canagliflozin, as NICE-recommended options for triple therapy.

All three drugs are already recommended for use on their own if a person cannot use metformin or other specific drugs, or in combination with metformin as dual therapy.

Professor Carole Longson, director of NICE’s centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs.

“This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.

“And as we’ve been able to publish this final guidance sooner because of positive draft recommendations, we hope that people who need this extra treatment option will benefit more quickly.”

How would qualify the communication between primary and secondary care services? (See OnMedica News 20/04)

Banner for OnMedica Views
NICE Annual Conference 2017
Wilmington Healthcare Limited, 6-14 Underwood Street, London, England, N1 7JQ
Registered in England and Wales, Reg No. 2530185
Twitter Facebook
A Wilmington Company